Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioMarin Kills Kyndrisa, But Duchenne Pursuit Not Over

Executive Summary

Seeing no clear path to approval in the US or Europe for its Duchenne muscular dystrophy drug Kyndrisa (drisapersen), BioMarin Pharmaceutical Inc. has decided to shelve the experimental medicine, along with three other first-generation follow-on products. But it said its Duchenne pursuit is not completely over, declaring it continues to "explore" its early-stage next-generation oligonucleotides as potential treatments for the disease, which generally kills patients before they reach 30 years.

You may also be interested in...



Deal Watch: Novartis Signs Deals In Migraine & Diabetes

Novartis will invest in the Calgary-based Parvus and collaborate on a Navacim candidate for type 1 diabetes. Japan's Sawai moves into the US market by acquiring Upsher-Smith's generics business, while Denovo acquires a suspended depression candidate from AMRI for its personalized development approach.

Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?

More and larger M&A deals could boost public biopharmaceutical companies, so investors will watch closely to see if Pfizer's $14bn Medivation acquisition kicks off a widespread spending spree. Speculation about who'll be bought next is in full swing.

Santhera Setback Could Have Wide-Reaching Effects For DMD Drugs

The DMD community faces another setback as FDA pushes back timelines for Santhera and its respiratory drug, pushing the market to question what will come for other DMD treatments in development.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC065316

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel